Aptar Pharma has provided the delivery system and regulatory support for Adapt Pharma’s Narcan, an FDA-approved nasally administered, needle-free medication that can stop or reverse the effects of an opioid overdose
Salim Haffar, president of Aptar Pharma, said: “Aptar Pharma leads the industry in nasal drug delivery expertise.
“We have collaborated closely with Adapt Pharma to ensure the rapid approval of this potentially life-saving product using our Unit-dose System (UDS).
“The regulations and requirements for market approvals are rapidly evolving and customers must seek out trusted partners like Aptar Pharma.”
Narcan contains naloxone which is an opioid antagonist. It is marketed in the US for emergency treatment of known or suspected opioid overdose.
Seamus Mulligan, chairman and CEO of Adapt Pharma, said: “The US is facing an unprecedented opioid overdose epidemic.
“By making Narcan Nasal Spray available, we hope to increase everyone’s access to emergency treatments across the US.”